Artivion, Inc. Stock Price, News & Analysis

Artivion (NYSE: AORT) has successfully closed transactions to exchange approximately $99.54 million of its 4.250% Convertible Senior Notes due 2025 for 4,334,347 shares of common stock. The company also made a cash payment of $1.7 million for accrued and unpaid interest to the note holders. Following these transactions, only $0.46 million in aggregate principal amount of the Notes remains outstanding.

CEO Pat Mackin emphasized that this effective retirement of convertible notes represents a significant milestone in strengthening Artivion's financial position, reducing leverage ratios, and enhancing balance sheet flexibility. J. Wood Capital Advisors LLC served as financial advisor for these exchange transactions.

Artivion (NYSE: AORT) has announced private exchange agreements with holders of its 4.250% Convertible Senior Notes due 2025. The company will repurchase approximately $95 million in principal amount of existing convertible notes in exchange for common stock. Based on the May 13 closing price of $28.91 per share, the exchange would result in the issuance of approximately 4.1 million shares. The company will also pay cash for accrued and unpaid interest. The exchange transactions are expected to close around May 28, 2025, subject to customary closing conditions. J. Wood Capital Advisors LLC served as financial advisor for the transaction.

Artivion (NYSE: AORT) reported its Q1 2025 financial results, showing revenue of $99.0 million, up 2% YoY (4% on constant currency). The company experienced strong product growth with stent grafts up 14%, On-X up 10%, and BioGlue up 7% YoY. However, preservation services declined 23% due to a cybersecurity incident. Q1 resulted in a net loss of $(0.5) million or $(0.01) per share, while adjusted EBITDA increased 1% to $17.5 million. Notably, Endospan's NEXUS TRIOMPHE IDE trial showed promising results with a 63% reduction in major adverse events. Artivion raised its 2025 revenue guidance to $423-435 million, projecting 11-14% growth, and expects adjusted EBITDA of $84-91 million, representing 18-28% growth.

Artivion (NYSE: AORT) presented promising clinical data from Endospan's NEXUS TRIOMPHE IDE trial at the 105th AATS Annual Meeting. The study evaluated 54 high-risk patients with chronic aortic dissection treated with the NEXUS stent graft system. At 30 days post-treatment, the results showed a significant 63% reduction in Major Adverse Events (MAE) rate at 13.0% compared to the 35.0% performance goal (p<0.001). The technical failure rate was notably low at 1.9% versus the 30.0% performance goal (p<0.001). The NEXUS device represents a minimally invasive alternative to open aortic arch replacement for high-risk patients, potentially extending treatment options to previously untreatable cases.

Artivion (NYSE: AORT) has scheduled the release of its first quarter 2025 financial results for Monday, May 5, 2025, after market close. The cardiac and vascular surgery company will host a teleconference call and live webcast at 4:30 p.m. ET on the same day.

The earnings discussion will feature a Q&A session led by Pat Mackin, Chairman, President and CEO. Interested parties can join the teleconference by dialing 201-689-8261 before 4:30 p.m. ET. A replay will be available at 877-660-6853 or 201-612-7415 (conference number: 13752340). The webcast and replay can be accessed through the Investors section at www.artivion.com under Webcasts & Presentations.

Artivion (NYSE: AORT), a cardiac and vascular surgery company specializing in aortic disease, has announced its participation in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference. The company will engage in a virtual fireside chat on March 18, 2025 at 10:40 a.m. ET.

Investors and interested parties can access the live webcast through the Investors page on Artivion's website (www.artivion.com). The recorded session will remain available for replay on the website for 90 days following the event.

Artivion (NYSE: AORT) reported its Q4 and full-year 2024 financial results. Q4 revenue reached $97.3 million, up 4% from Q4 2023, while full-year revenue grew 10% to $388.5 million. The company posted a Q4 net loss of $(16.5) million, or $(0.39) per share, and a full-year net loss of $(13.4) million.

Key growth drivers included On-X (10%), stent grafts (10%), and BioGlue (8%) in Q4. Latin America showed strong performance with 26% growth. The company received FDA Humanitarian Device Exemption for AMDS Hybrid Prosthesis and submitted its second PMA module.

For 2025, Artivion projects revenue between $420-435 million (10-14% growth) and adjusted EBITDA of $84-91 million (18-28% growth). The company noted a late November 2024 cybersecurity incident that impacted Q4 revenues but expects minimal impact on 2025 performance.

Artivion (NYSE: AORT) has scheduled the release of its fourth quarter and full year 2024 financial results for Monday, February 24, 2025, after market close. The company will host a teleconference call and live webcast at 4:30 p.m. ET on the same day, featuring Chairman, President and CEO Pat Mackin, followed by a Q&A session.

Participants can join the live teleconference by dialing 201-689-8261. A replay will be available approximately one hour after the event by calling 877-660-8653 (toll-free) or 201-612-7415, using conference number 13749878. Both the live webcast and replay will be accessible through the Investors section of Artivion's website.

Artivion (NYSE: AORT) presented one-year data from the AMDS PERSEVERE clinical trial at the 61st Annual Meeting of the Society of Thoracic Surgeons. The study analyzed outcomes of 93 participants following AMDS implantation for acute DeBakey Type I dissections with malperfusion.

Key findings show sustained benefits at one year with 80% patient survival. The trial demonstrated significantly better outcomes compared to historical controls, with all-cause mortality of 20.4% vs 42.7% at one year. Notable results include new disabling stroke (11.8%), renal failure/dialysis (20.4%), and myocardial infarction (2.2%).

Importantly, no distal anastomotic new entry (DANE) tears were detected in PERSEVERE study patients, compared to up to 70% occurrence in traditional treatments. The need for unanticipated aortic reoperations was low at 4.3%. The company expects PMA approval in late 2025.